Bridge Therapeutics®, based in Birmingham, Ala., is an innovative development-stage specialty pharmaceutical company pursuing U.S. Food and Drug Administration (FDA) and European Medicines Agency (EMA) approvals of a patented (U.S. Patent #8410092) drug combination, BT-205, for the treatment of chronic pain in opioid experienced patients. 

Pharmaceutical

Bridge Therapeutics

Bridge Therapeutics' headquarters in Center Point, AL, United States

David Bergstrom

Greg Sullivan

Tim Peara

Alton S. Kelley

Bob A. Rappaport

Joseph V. Pergolizzi

Joseph Mullin

Robert B. Raffa

Michael Fishman

Description

People

Jobs